Related Experiment Video
Updated: Jun 28, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
Management of erectile dysfunction in diabetes: an update for 2008
David Price1, Geoffrey Hackett
1Morriston Hospital, ABM University Trust, Swansea, United Kingdom. dave.price@swansea-tr.wales.nhs.uk
Abstract:
Tumescence occurs as a result of nitric oxide (NO)-mediated smooth muscle relaxation of the erectile tissue leading to engorgement of the corpus cavernosum. The process is initiated by neuronal NO release and maintained by NO released by the local vascular endothelium. Erectile dysfunction (ED) affects 30% to 40% of diabetic men and occurs as a result of endothelial dysfunction and autonomic neuropathy. The close association with endothelial dysfunction means ED is an early marker of cardiovascular risk. Managing ED is easy and must be part of a diabetes care service. Phosphodiesterase type 5 inhibitors are the treatment of choice, but are effective in only 50% to 60% of diabetic men. The reasons for nonresponsiveness remain uncertain and research is needed in this area. There has been much recent interest in the potential relationship between late-onset hypogonadism and diabetes, but there is no evidence of a causal relationship and the evidence in favor of treating borderline hypogonadism in diabetes is limited.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetic Retinopathy
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Diabetes Mellitus: Type 2 and Gestational